Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 15/20 | 0.68 |
| ▸ | SRD5A2 | P31213 | 7/20 | 0.68 |
| ▸ | AR | P10275 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5214213 | 1.00 | SRD5A1 (0.68) | SRD5A1SRD5A2ARLMNAABCB11 | |
| SCHEMBL5211958 | 0.92 | AR (0.72) | SRD5A1SRD5A2AR | |
| SCHEMBL5212063 | 0.92 | AR (0.72) | SRD5A1SRD5A2AR | |
| SCHEMBL7075042 | 0.92 | AR (0.72) | SRD5A1SRD5A2AR | |
| SCHEMBL7079738 | 0.88 | SRD5A1 (0.64) | SRD5A1SRD5A2AR | |
| SCHEMBL5215956 | 0.88 | SRD5A1 (0.64) | SRD5A1SRD5A2AR | |
| SCHEMBL5215064 | 0.85 | AR (0.84) | SRD5A1SRD5A2ARLMNAABCB11 | |
| SCHEMBL7080869 | 0.85 | AR (0.84) | SRD5A1SRD5A2ARLMNAABCB11 | |
| SCHEMBL7075701 | 0.84 | AR (0.55) | SRD5A1SRD5A2AR | |
| SCHEMBL5215405 | 0.84 | AR (0.55) | SRD5A1SRD5A2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6645974-B2 | Administering an androstamide compound; osteoporosis, anticancer agents, glandular disorders | MERCK & CO., INC. | 2003-11-11 | — | — | US | claimed |
| US-20030065004-A1 | Androgen receptor modulators and methods for use thereof | MERCK SHARP & DOHME CORP. | 2003-04-03 | — | — | US | claimed |
| US-6645974-B2 | Administering an androstamide compound; osteoporosis, anticancer agents, glandular disorders | MERCK & CO., INC. | 2003-11-11 | — | — | US | disclosed |
| US-20030065004-A1 | Androgen receptor modulators and methods for use thereof | MERCK SHARP & DOHME CORP. | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065004-A1 | Androgen receptor modulators and methods for use thereof | AR, FSHR, SHBG | SRD5A1 58/4885SRD5A2 80/4885AR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.